Cancers MDPI

@Cancers_MDPI

An international, journal addressing both clinical and basic science issues related to research. Meet us at ESMO 2019 (Spain), Stand !

Vrijeme pridruživanja: ožujak 2016.

Tweetovi

Blokirali ste korisnika/cu @Cancers_MDPI

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Cancers_MDPI

  1. Prikvačeni tweet
    20. lip 2019.

    Cancers Receiving 2018 Updated of 6.162: Cancers received an updated Journal Impact Factor of 6.162 in the recent release of the Journal Citation Reports®. It now ranks 31/229 (Q1) in the category 'Oncology'. More information:

    Poništi
  2. proslijedio/la je Tweet
    14. sij

    1/ Hear ye, hear ye! Delighted to announce the launch of the Special Issue on "Metabolic Reprogramming and Vulnerabilities in Cancer" in , co-edited with . All .

    Prikaži ovu nit
    Poništi
  3. 15. sij

    Meet with our editors at booth #21123 at 2020 Annual Meeting, Chicago, IL, USA, 29 May-2 June.

    Poništi
  4. 2. sij

    Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in : blocking LDH-A in the tumor might improve the efficacy of anti-PD-1 therapy. Full-Text

    Poništi
  5. 2. sij

    Latent Cytomegalovirus Infection in Female Mice Increases Metastasis: treating or preventing HCMV infections may increase the life expectancy of breast cancer patients by decreasing metastasis. Full-Text

    Poništi
  6. 2. sij

    Review: Importance of TRAIL Molecular Anatomy in Receptor Oligomerization and Signaling. Implications for Therapy: oligomerization status of TRAIL receptors; the implications for cancer treatment when using TRAIL-based therapies. View Full-Text

    Poništi
  7. 2. sij

    The Head and Neck Squamous Cell Carcinoma Microenvironment as a Potential Target for Cancer Therapy: focusing on the mechanism of intercellular crosstalk manipulation for potential therapeutic application. Full-Text

    Poništi
  8. 2. sij

    Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies: In this review, we summarized the latest findings on PCPG genetics, novel therapeutic targets, and perspectives for future . View Full-Text

    Poništi
  9. 30. pro 2019.

    Review: Tailoring Treatment: Implications of BRCA1/2 Mutations: future trends with respect to BRCA mutation carriers. Full-Text:

    Poništi
  10. 30. pro 2019.

    New Phosphorylation Sites of Rad51 by c-Met Modulates Presynaptic Filament Stability: these results confirm the role of these modifications in the regulation of the BRCA2-RAD51 interaction and underline the importance of c-MET in DNA damage response. View Full-Text

    Poništi
  11. 26. pro 2019.

    Shi-Long Lu et al Review - The Role of MicroRNAs in Recurrence and Metastasis of Head and Neck Squamous Cell Carcinoma an overview of microRNAs involved in these processes

    Poništi
  12. 26. pro 2019.

    FOXK2 Transcription Factor and Its Emerging Roles in Cancer: the emerging functions of FOXK2 as a regulator of a broad range of cancer features, such as cell proliferation and survival, DNA damage, metabolism, migration, invasion and metastasis.

    Poništi
  13. 26. pro 2019.

    Sierko et al: Review- Personalized Radiation Therapy in Cancer Pain Management : the possibilities and effectiveness of individual patient-tailored conventional and innovative radiation therapy approaches aiming at pain relief in cancer patients

    Poništi
  14. 26. pro 2019.

    Ferreira et al : Review - MRI of Uveal : this dedicated MRI protocol provides high-quality imaging of UM, which can be used to improve its diagnosis, treatment planning, and follow-up. View Full-Text

    Poništi
  15. 26. pro 2019.

    Review: BRCA2 and Other DDR Genes in Prostate Cancer - summarize the available evidence regarding the prevalence of somatic and germline DDR defects in prostate cancer... View Full-Text

    Poništi
  16. 26. pro 2019.

    "we discuss JAK-STAT biology in the context of immunity and cancer, the consequences of pathway perturbations and current therapeutic interventions, to provide insight and consideration for future targeting innovations"

    Poništi
  17. 26. pro 2019.

    "high ANXA2 levels in circulating EVs were associated with high risk of recurrence and non-endometrioid histology suggesting a potential value as a prognostic biomarker in EC. ExoGAG technology can be a robust technique for the clinical implementation of circulating EVs analyses"

    Poništi
  18. 26. pro 2019.

    " the results reveal that the overexpression of IF1 acts as a tumor suppressor in CRC with an important anti-metastatic role, thus supporting IF1 as a potential therapeutic target in CRC."

    Poništi
  19. 26. pro 2019.

    "NSCLC patients treated with ICIs bear a consistent risk for thrombotic complications, with a detrimental effect on survival. The impact of antiplatelet drugs on ICIs efficacy deserves further investigation in prospective trials."

    Poništi
  20. 11. pro 2019.

    Pannexin 2 Localizes at ER-Mitochondria Contact Sites: Panx2 localizes at ER-mitochondria contact sites in mammalian cells and sensitizes cells to apoptotic stimuli. View Full-Text

    Poništi
  21. 11. pro 2019.

    "This review provides a succinct overview of emerging roles of ER stress and the UPR in cancer-induced skeletal muscle wasting"

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·